ABBV AbbVie Inc.

neutral SHIFT track record → $208.99 +0.57 (+0.3%)
Mkt Cap $369B P/E 88.0 fwd 13.0 52wk $168.54 - $244.81 Earnings 2026-04-29 1h ago
Insider selling: $141,732,846 sold by 25 insiders (30d)
Est. revisions: -7.1%
Factor Model (net -2.4)

Factor Model

net -2.4 5.7 / 10
Est. Revisions
-0.4
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
-0.5

AbbVie cuts guidance amid R&D costs, trial hope

Watch: Watch AbbVie's detailed Q1 report and any updates on oncology pipeline integration into its portfolio for signs of recovery or further risk.

AbbVie lowered its Q1 2026 EPS guidance to $2.56-$2.60, missing consensus of $2.99, and cut full-year EPS guidance to $13.96-$14.16 from $14.37-$14.57. The Q1 impact included $744M pre-tax expenses reducing EPS by $0.41. Insider selling accelerated with over $141 million sold recently. Meanwhile, AbbVie benefits indirectly as Revolution Medicines' pancreatic cancer drug showed a 60% death risk reduction in Phase 3, boosting related sector optimism.

Lowered earnings guidance and high R&D expenses pressure near-term stock performance, but rising clinical trial successes in the oncology space could provide a medium-term catalyst supporting clinical pipeline confidence.

Evidence

2h ago Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally yahoo-finance
2d ago Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy? yahoo-finance
3d ago Insider sell by STEWART JEFFREY RYAN (ABBV): $12,359,504
3d ago Insider sell by GONZALEZ RICHARD A (ABBV): $20,263,020
3d ago Insider sell by GONZALEZ RICHARD A (ABBV): $12,403,580
3d ago Insider sell by GONZALEZ RICHARD A (ABBV): $49,497,875
5d ago Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead yahoo-finance
9d ago AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns yahoo-finance
7 older signals
26d ago AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform
29d ago William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
34d ago RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
38d ago This 5-Star ETF Pays Monthly Dividends and Has Never Missed in 19 Years
38d ago AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
40d ago Renaissance 13F (2025Q4):. New position in AMZN ($205,645,092) +425 more. Exited
42d ago AbbVie announces $380m investment in North Chicago API facilities
Fundamentals & Data ▾
AbbVie Inc. Healthcare · Drug Manufacturers - General
Mkt Cap
$369B
P/E
88.0 fwd 13.0
Beta
0.36
Div Yield
335.00%
52w Range
$168.54 - $244.81
Short Interest
20.1M 1.27%
Days to Cover
2.7 -8%
Technicals downtrend
from 52w Hi
-0.8%
1w return
-0.8%
Insiders
selling 0B / 2S
EPS Estimate
$2.80 -7.1% 30d 0up / 7dn
Est. Dispersion
18% 20 analysts
Analyst Target
$249 $184 - $299
Options P/C
0.21
Insider Cluster
strong sell 0B / 9S
Fund Convergence
strong D.E. Shaw, Citadel, Two Sigma, Bridgewater
Financials
Revenue
$16.6B +10% YoY
FCF
$4.9B
Gross Margin
73%
Op Margin
35%
Momentum: accelerating
Top Holders
D.E. Shaw $3.4B
Citadel $960M
Two Sigma $38M
Bridgewater $3M
Recent Filings & Data
insider trade 72
net selling · $141,732,846 sold
25 insiders · 72 transactions (30d)
Recent transactions
PURDUE DAVID R. · sell · $1,221,519
SIATIS PERRY C. · sell · $4,375,549
SIATIS PERRY C. · sell · $5,147,630
SIATIS PERRY C. · exercise · $3,863,458
MICHAEL ROBERT A. · award
STEWART JEFFREY RYAN · award
DONOGHOE NICHOLAS · award
REENTS SCOTT T. · award
SIATIS PERRY C. · award
THAKKAR ROOPAL · award
PURDUE DAVID R. · award
CRUM DEMETRIS D · award
SALEKI-GERHARDT AZITA · award
SALEKI-GERHARDT AZITA · sell · $8,407,055
SALEKI-GERHARDT AZITA · exercise · $2,324,418
DONOGHOE NICHOLAS · sell · $2,639,253
FREYMAN THOMAS C · award
FALK THOMAS J · award
AUSTIN ROXANNE SCHUH · award
TILTON GLENN FLETCHER · award
WADDELL FREDERICK H · award
BURNSIDE WILLIAM H L · award
MEYER MELODY B · award
ROBERTS REBECCA B. · award
DAVIS JENNIFER L · award
QUAGGIN SUSAN E · award
RAPP EDWARD J · award
ALPERN ROBERT J · award
HART BRETT J · award
GONZALEZ RICHARD A · other
STEWART JEFFREY RYAN · sell · $12,359,504
STEWART JEFFREY RYAN · exercise · $2,030,814
REENTS SCOTT T. · sell · $3,746,527
GONZALEZ RICHARD A · sell · $20,263,020
SIATIS PERRY C. · sell · $5,822,402
SIATIS PERRY C. · exercise · $2,879,040
RICHMOND TIMOTHY J · sell · $4,472,039
BUCKBEE KEVIN K · sell · $3,853,372
BUCKBEE KEVIN K · exercise · $1,601,313
RICHMOND TIMOTHY J · sell · $6,070,036
RICHMOND TIMOTHY J · exercise · $2,539,936
SIATIS PERRY C. · sell · $1,143,453
GONZALEZ RICHARD A · award
MICHAEL ROBERT A. · award
STEWART JEFFREY RYAN · award
DONOGHOE NICHOLAS · award
REENTS SCOTT T. · award
SIATIS PERRY C. · award
BUCKBEE KEVIN K · award
THAKKAR ROOPAL · award
RICHMOND TIMOTHY J · award
SALEKI-GERHARDT AZITA · award
BUCKBEE KEVIN K · sell · $310,032
BUCKBEE KEVIN K · exercise · $168,300
GONZALEZ RICHARD A · other
SALEKI-GERHARDT AZITA · other
GONZALEZ RICHARD A · sell · $12,403,580
GONZALEZ RICHARD A · sell · $49,497,875
GONZALEZ RICHARD A · exercise · $21,919,048
GONZALEZ RICHARD A · other
FREYMAN THOMAS C · award
AUSTIN ROXANNE SCHUH · award
TILTON GLENN FLETCHER · award
WADDELL FREDERICK H · award
BURNSIDE WILLIAM H L · award
MEYER MELODY B · award
ROBERTS REBECCA B. · award
DAVIS JENNIFER L · award
QUAGGIN SUSAN E · award
RAPP EDWARD J · award
ALPERN ROBERT J · award
HART BRETT J · award
15 signals · latest 2h ago

Get alerted when ABBV changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.

All stocks → Our calls → How it works →